Products / Oncology and Hematology

Liquid Biopsy

Liquid biopsy is an innovative method that analyzes genetic information from tumor cells in blood samples for cancer diagnosis, monitoring treatment response, and tracking disease progression.
Used as an alternative or complement to traditional tissue biopsy, liquid biopsy offers a non-invasive, repeatable, and rapid solution.

Why Liquid Biopsy?

Because diagnosis is no longer tissue-dependent.

Next-generation sequencing-based liquid biopsy tests play a critical role in early diagnosis, determining targeted treatment, and supporting immunotherapy decisions.

Is resistance developing?

Archer LIQUIDPlexTM ctDNA 28 Panel analyzes cancer-related genes to detect clinically meaningful mutations. It can perform highly sensitive analysis on cfDNA (circulating free DNA) and ctDNA (circulating tumor DNA). Supports targeted treatment decisions with comprehensive biomarker analysis.

Genomic analysis of metastatic and advanced-stage cancer patients

Biomarker detection in clinical trials

Monitoring genetic changes in cancer patients without the need for repeat biopsies

Are you unable to perform a biopsy?

MSK ACCESS powered by SOPHiA DDMTM enables the analysis of 147 cancer-related genes (~20,000x) in cases where biopsy is not possible. SOPHiA DDMTM provides comprehensive reports by analyzing data quickly and accurately. It matches molecular profiles with clinical data using OncoPortalTM Plus.

Visible mutations may be misleading.

CHiP (Clonal Hematopoiesis of Indeterminate Potential) means that variants detected in blood samples may actually be due to clonal proliferation in hematopoietic cells rather than a tumor.

This situation can lead to misleading results, especially in liquid biopsy samples.

MSK ACCESS powered by SOPHiA DDM filters out CHiP-derived false positives by distinguishing between somatic and germline mutations.

Monitor Treatment Response Using ctDNA

TruSight Oncology 500 ctDNA v2 detects mutations, fusions, copy number alterations, and indels across more than 500 cancer-related genes. It operates with high sensitivity even at low ctDNA levels, reducing the need for repeat biopsies.

It also helps identify patients suitable for immunotherapy by measuring TMB (Tumor Mutation Burden) and MSI (Microsatellite Instability).